Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Biotech
ASH: Novartis details ianalumab's phase 3 rare blood disease win
If the combo therapy's boosted platelet counts persist even longer, it could "change the treatment paradigm" for primary immune thrombocytopenia.
Darren Incorvaia
Dec 9, 2025 7:30am
Novartis pens $1.7B atopic disease pact with British biotech
Dec 9, 2025 3:57am
Why Novartis CEO was willing to pay top dollar for Avidity
Nov 20, 2025 4:37am
Novartis' resistance-busting malaria drug hits phase 3 goal
Nov 13, 2025 7:05am
Novartis’ phase 3 wins in Sjögren's see high placebo effect
Oct 29, 2025 12:03pm
Novartis pays $12B for late-stage dystrophy biotech Avidity
Oct 26, 2025 4:01pm
